EVE Health Group Limited (AU:EVE)
ASX:EVE
Want to see AU:EVE full AI Analyst Report?
Top Page
EVE Health Group Limited
(Sydney:EVE)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.02
▼(-5.00% Downside)
Action:Reiterated
Date:11/18/25
EVE Health Group Limited's overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and profitability issues. Technical analysis indicates bearish trends, and valuation metrics are unattractive due to negative earnings. The absence of earnings call insights and corporate events further limits the score.
Positive Factors
Low leverage / conservative capital structure
A very low debt-to-equity ratio provides durable financial flexibility and lower solvency risk, enabling the business to fund operations or small investments without heavy interest burdens. Over 2-6 months this supports resilience versus more leveraged peers and preserves strategic optionality.
Negative Factors
Declining revenues
Material top-line contraction weakens scale and intensifies pressure on unit economics; declining revenues reduce ability to absorb fixed costs and limit funds for marketing or product development. Without structural revenue stabilization, margin recovery will be difficult to sustain.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / conservative capital structure
A very low debt-to-equity ratio provides durable financial flexibility and lower solvency risk, enabling the business to fund operations or small investments without heavy interest burdens. Over 2-6 months this supports resilience versus more leveraged peers and preserves strategic optionality.
Read all positive factors
EVE Health Group Limited (EVE) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$7.05M
Dividend YieldN/A
Average Volume (3M)774.07K
Price to Earnings (P/E)―
Beta (1Y)0.43
Revenue Growth-32.09%
EPS Growth34.85%
CountryAU
Employees3
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding352,326,600
10 Day Avg. Volume491,958
30 Day Avg. Volume774,070
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.22
Price to Sales (P/S)2.49
P/FCF Ratio-2.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
EVE Health Group Limited Business Overview & Revenue Model
Company Description
Based in Subiaco, Australia, Eve Health Group Limited, originally incorporated in 2003 as EVE Investments Limited, is an international provider of health, wellness, and nutritional products. The company operates across Australia, New Zealand, the ...
How the Company Makes Money
null...
EVE Health Group Limited Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.36M | 1.73M | 2.13M | 2.33M | 2.01M | 2.80M |
| Gross Profit | 385.07K | 824.03K | 876.96K | 827.83K | -1.00M | -713.50K |
| EBITDA | -1.65M | -1.43M | -1.51M | -2.18M | -4.53M | -2.79M |
| Net Income | -1.62M | -1.58M | -1.90M | -4.04M | -5.37M | -3.63M |
Balance Sheet | ||||||
| Total Assets | 4.07M | 4.12M | 2.52M | 4.13M | 8.07M | 11.92M |
| Cash, Cash Equivalents and Short-Term Investments | 929.66K | 903.42K | 106.17K | 192.48K | 1.10M | 3.16M |
| Total Debt | 38.51K | 91.28K | 74.85K | 4.28K | 492.39K | 1.01M |
| Total Liabilities | 307.63K | 572.45K | 1.30M | 1.01M | 1.14M | 1.74M |
| Stockholders Equity | 3.76M | 3.55M | 1.22M | 3.12M | 6.93M | 10.19M |
Cash Flow | ||||||
| Free Cash Flow | -1.54M | -1.62M | -1.11M | -1.65M | -3.80M | -2.51M |
| Operating Cash Flow | -1.54M | -1.62M | -1.11M | -1.65M | -3.77M | -2.24M |
| Investing Cash Flow | 302.79K | 2.13M | 874.27K | 498.46K | -26.05K | -263.38K |
| Financing Cash Flow | 1.78M | 279.09K | 146.37K | 240.69K | 1.74M | 529.43K |
EVE Health Group Limited Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
44 Neutral | AU$7.04M | -1.79 | -322.76% | ― | 12.52% | 52.17% | |
44 Neutral | AU$24.64M | -25.77 | -321.20% | ― | 2.96% | -866.67% | |
44 Neutral | AU$6.99M | -0.01 | 226.76% | ― | -32.83% | 83.37% | |
44 Neutral | AU$5.68M | -1.28 | -35.12% | ― | 96.60% | 67.50% | |
41 Neutral | AU$7.05M | -2.30 | -44.35% | ― | -32.09% | 34.85% |
* Consumer Defensive Sector Average
AU:EVE
EVE Health Group Limited
0.02
>-0.01
-33.33%
AU:CCO
Fiji Kava Limited
―
―
―
AU:HCT
Holista Colltech Limited
0.07
0.01
19.64%
AU:NGS
Nutritional Growth Solutions Ltd.
0.02
>-0.01
-8.70%
AU:OMG
Forbidden Foods Ltd
0.01
-0.01
-50.00%
EVE Health Group Limited Corporate Events
EVE Health Group trims potential dilution as 4 million options lapse
Jun 19, 2026
EVE Health Group Limited has notified the market of a change to its capital structure, advising that a tranche of options quoted under the ASX code EVEAI has ceased. The affected securities were 4,000,000 options exercisable at $0.06 and expiring ...
EVE Health Group director increases family’s indirect shareholding via off-market transfer
May 22, 2026
EVE Health Group non-executive director Gregory William Fry has updated his disclosed holdings following an off-market transfer of 850,000 ordinary shares on 21 May 2026. The shares, acquired for $17,850, were added to the indirect holdings regist...
EVE Health Group Issues 135.4 Million Unquoted Options for Future Capital Flexibility
May 8, 2026
EVE Health Group Limited has issued a substantial tranche of unquoted options as part of its capital management strategy, creating two new classes of securities. The company has granted 130.4 million options exercisable at AUD 0.04 expiring on 30 ...
EVE Health Director Boosts Indirect Stake via Share Placement
May 8, 2026
EVE Health Group Limited has reported a change in the holdings of director Stuart Gunzburg, who increased his indirect stake through entities associated with his family and investment vehicles. The update, lodged under ASX listing rule 3.19A.2, re...
EVE Health Group Seeks Quotation for 2.75 Million New Shares
May 8, 2026
EVE Health Group Limited has applied for quotation on the ASX of 2,750,000 ordinary fully paid shares, with the securities to be issued on May 8, 2026. The new share quotation, which follows a previously announced transaction, will modestly expand...
EVE Health Shareholders Back Capital Resolutions at General Meeting
May 8, 2026
EVE Health Group reported that all resolutions put to shareholders at its 8 May 2026 General Meeting were passed by poll, signalling strong investor support for recent capital initiatives and board-endorsed measures. The approved resolutions inclu...
EVE Health launches Libbo in Australia and broadens reformulated drug pipeline
Apr 28, 2026
EVE Health Group has begun the commercial launch of Libbo, its oral dissolving film treatment for erectile dysfunction, in Australia, supported by the new men’s health platform stiffissue.com that integrates digital education, telehealth pre...
EVE Health Group Names Ben Rohr CEO, Refines Leadership to Drive Product Commercialisation
Apr 27, 2026
EVE Health Group Limited has appointed former Chief Operating Officer Ben Rohr as Chief Executive Officer, effective immediately, highlighting the board’s push to accelerate commercialisation of its product portfolio and drive disciplined gr...
EVE Health Group Calls May 2026 General Meeting, Urges Proxy Voting
Apr 7, 2026
EVE Health Group Limited has called a general meeting of shareholders to be held on 8 May 2026 in Subiaco, Western Australia, outlining how investors can participate and vote. Shareholders are encouraged to lodge proxy forms in advance, underscori...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.